Lifitegrast

1025967-78-5

C29H24Cl2N2O7S

DMSO : >= 29 mg/mL (47.12 mM)

Cytoskeleton

Lifitegrast (SAR 1118) is an integrin lymphocyte function-associated antigen-1 (LFA-1) antagonist; inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. IC50 & Target: IC50: 2.98 nM (LFA-1)^[1] In Vitro: Lifitegrast (SAR 1118) is a novel small molecule integrin antagonist that inhibits T cell-mediated inflammation by blocking the binding of two important cell surface proteins (lymphocyte function-associated antigen 1 and intercellular adhesion molecule 1), thus lessening overall inflammatory responses. Lifitegrast (SAR 1118) strongly inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM^[1]. In Vivo: Lifitegrast (SAR 1118), has potent anti-inflammatory activity on corneal inflammation induced by antibiotic-killed P. aeruginosa and S. aureus in the presence of a silicone hydrogel lens with the optimal application being a 1% solution applied either 2 or 3 times prior. Topical application of Lifitegrast (SAR 1118) to the corneal surface of healthy adults is safe and well tolerated^[2]. Lifitegrast (SAR 1118) ophthalmic drops administered thrice daily deliver therapeutic levels of Lifitegrast (SAR 1118) in the retina and can alleviate the retinal complications associated with diabetes^[3].